MedTrace Logo

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-03-12

Study results available
· View outcomes & findings →

Summary

A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.

Conditions

Interventions

DRUG

Bermekimab Monoclonal Antibody 200 mg

200 mg subcutaneous injection

DRUG

Bermekimab Monoclonal Antibody 400 mg

400 mg subcutaneous injection

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-21
Primary Completion
2018-12-04
Completion
2018-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03496974 on ClinicalTrials.gov